Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016
Published Jul 27, 2016
61 pages — Published Jul 27, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016, provides in depth analysis on Beta Nerve Growth Factor (Beta NGF or NGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
- The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic

  
Source:
Document ID
GMDHC0413TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Beta Nerve Growth Factor (Beta NGF or NGF) Overview71
Therapeutics Development83
  Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Stage of Development81
  Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Therapy Area91
  Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Indication101
Beta Nerve Growth Factor (Beta NGF or NGF) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Beta Nerve Growth Factor (Beta NGF or NGF) Products under Development by Companies132
Beta Nerve Growth Factor (Beta NGF or NGF) Therapeutics Assessment157
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action162
  Assessment by Route of Administration182
  Assessment by Molecule Type202
Beta Nerve Growth Factor (Beta NGF or NGF) Companies Involved in Therapeutics Development2210
  Amgen Inc.221
  Astellas Pharma Inc.231
  Chiesi Farmaceutici SpA241
  Fujimoto Pharmaceutical Corporation251
  Krenitsky Pharmaceuticals Inc.261
  MedImmune, LLC271
  NsGene A/S281
  Pfizer Inc.291
  Regeneron Pharmaceuticals, Inc.301
  Staidson (Beijing) Biopharmaceuticals Co., Ltd.311
Beta Nerve Growth Factor (Beta NGF or NGF) Drug Profiles3217
  AS-288640100 Drug Profile321
  fasinumab Drug Profile333
  fulranumab Drug Profile363
  Gene Therapy to Activate NGF for Undisclosed Indication Drug Profile391
  KP-544 Drug Profile401
  MEDI-7352 Drug Profile411
  NsG-0202 Drug Profile421
  RBM-004 Drug Profile431
  Recombinant Protein to Target NGF for Undisclosed Indication Drug Profile441
  Small Molecule for Neurotrophic Keratitis Drug Profile451
  tanezumab Drug Profile463
Beta Nerve Growth Factor (Beta NGF or NGF) Dormant Projects492
Beta Nerve Growth Factor (Beta NGF or NGF) Discontinued Products511
Beta Nerve Growth Factor (Beta NGF or NGF) Featured News &Press Releases528
  May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain521
  Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain531
  Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab531
  Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors531
  Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909541
  Dec 27, 2010: FDA Halts Development Of Regeneron s Pain Drug551
  Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program551
  Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab551
  May 12, 2010: Regeneron Provides Initial Data On REGN475561
  Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010561
  Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202571
  Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx571
  Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains581
  Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer s Disease591
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Beta-Nerve-Growth-Factor-Beta-NGF-or-NGF-Pipeline-Review-H2-2016-2088-16295>
  
APA:
Global Markets Direct - Market Research. (2016). Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Beta-Nerve-Growth-Factor-Beta-NGF-or-NGF-Pipeline-Review-H2-2016-2088-16295>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.